1. Home
  2. AGPU vs MAIA Comparison

AGPU vs MAIA Comparison

Compare AGPU & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axe Compute Inc. Common Stock

AGPU

Axe Compute Inc. Common Stock

BUY

Current Price

$7.87

Market Cap

83.5M

Sector

N/A

ML Signal

BUY

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.15

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGPU
MAIA
Founded
2002
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
69.2M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
AGPU
MAIA
Price
$7.87
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
281.5K
★ 463.0K
Earning Date
11-13-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
★ $125,284.00
N/A
Revenue This Year
$48,110.47
N/A
Revenue Next Year
$614.07
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$0.87
52 Week High
$13.49
$3.19

Technical Indicators

Market Signals
Indicator
AGPU
MAIA
Relative Strength Index (RSI) 34.74 44.40
Support Level $7.44 N/A
Resistance Level $9.30 $1.47
Average True Range (ATR) 0.91 0.05
MACD -0.35 0.00
Stochastic Oscillator 6.96 49.33

Price Performance

Historical Comparison
AGPU
MAIA

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: